Encompass Health (NYSE:EHC – Get Free Report) issued an update on its FY 2024 earnings guidance on Monday morning. The company provided EPS guidance of 4.190-4.330 for the period, compared to the consensus EPS estimate of 4.190. The company issued revenue guidance of $5.3 billion-$5.4 billion, compared to the consensus revenue estimate of $5.3 billion. Encompass Health also updated its FY24 guidance to $4.19-$4.33 EPS.
Analyst Upgrades and Downgrades
EHC has been the topic of a number of recent research reports. KeyCorp started coverage on shares of Encompass Health in a research note on Friday, October 11th. They issued an “overweight” rating and a $115.00 price objective on the stock. Leerink Partners started coverage on Encompass Health in a report on Wednesday, July 10th. They issued an “outperform” rating and a $100.00 price objective for the company. Stephens restated an “overweight” rating and set a $105.00 target price on shares of Encompass Health in a report on Tuesday, August 6th. Barclays lowered their price target on Encompass Health from $113.00 to $109.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, Truist Financial boosted their price objective on shares of Encompass Health from $104.00 to $108.00 and gave the company a “buy” rating in a report on Monday, October 14th. Eight research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $104.67.
View Our Latest Stock Report on Encompass Health
Encompass Health Stock Down 0.4 %
Encompass Health (NYSE:EHC – Get Free Report) last announced its earnings results on Monday, August 5th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.10. Encompass Health had a return on equity of 17.83% and a net margin of 7.88%. The business had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.30 billion. During the same quarter last year, the firm earned $0.95 EPS. Encompass Health’s revenue for the quarter was up 9.6% compared to the same quarter last year. On average, research analysts forecast that Encompass Health will post 4.18 earnings per share for the current fiscal year.
Encompass Health Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be issued a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.73%. The ex-dividend date of this dividend is Thursday, January 2nd. Encompass Health’s payout ratio is 17.35%.
Encompass Health announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, July 24th that allows the company to repurchase $500.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 5.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.
Insiders Place Their Bets
In other news, CFO Douglas E. Coltharp sold 12,260 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $86.34, for a total value of $1,058,528.40. Following the completion of the transaction, the chief financial officer now owns 136,227 shares in the company, valued at $11,761,839.18. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.10% of the company’s stock.
Encompass Health Company Profile
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Featured Stories
- Five stocks we like better than Encompass Health
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Inflation Risk Rising, Key Trades Investors Are Making Now
- What Does a Stock Split Mean?
- 3 Oil Stocks to Watch Before Earnings Come Out
- 3 Healthcare Dividend Stocks to Buy
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.